- Report
- January 2026
- 186 Pages
Global
From €4177EUR$4,500USD£3,487GBP
- Report
- February 2026
- 250 Pages
Global
From €4168EUR$4,490USD£3,479GBP
- Report
- July 2026
- 160 Pages
Global
From €3082EUR$3,320USD£2,573GBP
€3852EUR$4,150USD£3,216GBP
- Report
- November 2026
- 182 Pages
Global
From €5430EUR$5,850USD£4,533GBP
- Report
- February 2026
- 250 Pages
Global
From €4168EUR$4,490USD£3,479GBP
- Report
- September 2026
- 186 Pages
Global
From €3291EUR$3,545USD£2,747GBP
€3656EUR$3,939USD£3,052GBP
- Report
- May 2026
- 469 Pages
Global
From €4595EUR$4,950USD£3,836GBP
- Report
- October 2026
- 436 Pages
Global
From €4595EUR$4,950USD£3,836GBP
- Report
- September 2026
- 200 Pages
Global
From €2311EUR$2,490USD£1,929GBP
- Report
- January 2026
- 184 Pages
Global
From €3291EUR$3,545USD£2,747GBP
€3656EUR$3,939USD£3,052GBP
- Report
- December 2025
- 176 Pages
Global
From €5523EUR$5,950USD£4,611GBP
- Report
- April 2026
- 144 Pages
Global
From €3712EUR$3,999USD£3,099GBP
- Report
- February 2026
- 250 Pages
Global
From €4168EUR$4,490USD£3,479GBP
- Report
- February 2026
- 250 Pages
Global
From €4168EUR$4,490USD£3,479GBP
- Report
- February 2026
- 250 Pages
Global
From €4168EUR$4,490USD£3,479GBP
- Report
- July 2026
- 113 Pages
Global
From €4409EUR$4,750USD£3,681GBP
- Report
- August 2026
- 160 Pages
Global
From €3082EUR$3,320USD£2,573GBP
€3852EUR$4,150USD£3,216GBP
- Report
- August 2026
- 52 Pages
Global
From €6961EUR$7,500USD£5,812GBP
- Report
- February 2026
- 200 Pages
Europe
From €2775EUR$2,990USD£2,317GBP
- Report
- September 2025
- 447 Pages
Global
From €4595EUR$4,950USD£3,836GBP

The Chlamydia Test market within the In Vitro Diagnostics (IVD) industry is a rapidly growing segment. Chlamydia is the most commonly reported sexually transmitted infection in the United States, and the demand for testing is increasing. Tests for Chlamydia are typically performed using nucleic acid amplification tests (NAATs) or antigen detection tests. These tests are used to detect the presence of Chlamydia trachomatis, the bacterium that causes the infection.
The Chlamydia Test market is driven by the increasing prevalence of the infection, the availability of rapid and accurate tests, and the growing awareness of the importance of early diagnosis and treatment. The market is also supported by government initiatives to promote testing and the availability of reimbursement for testing.
The Chlamydia Test market is highly competitive, with a number of companies offering tests. These include Abbott, Becton Dickinson, Roche, Siemens, and Hologic. Show Less Read more